Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(1):122–126. doi: 10.1038/sj.bjc.6690660

Expression of high p53 levels in colorectal cancer: a favourable prognostic factor

E Adrover 1, M L Maestro 2, M T Sanz-Casla 2, V del Barco 2, J Cerdán 3, C Fernández 4, J L Balibrea 3
PMCID: PMC2374355  PMID: 10487622

Abstract

The expression of p53 protein was examined in a series of 111 colorectal cancer adenocarcinomas with a long follow-up. A quantitative luminometric immunoassay (LIA) was used for the measurement of wild-type and mutant p53 protein in extracts from colorectal tumour cytosols, p53 being detected in 42% of the samples (range 0.0–52 ng mg−1). Using an arbitrary cut-off value of 2.7 ng mg−1, 25% of the tumours were classified as manifesting high p53 levels. There was no association of p53 expression with patient age, sex, serum preoperative carcinoembryonic antigen (CEA) levels, tumour site and size, nodal status or TNM stage. Significant and independent correlation was found to exist between high p53 levels and prolonged disease-free survival (P = 0.05) at a median follow-up of 60 months. This survival advantage was most apparent among stage III cancer patients. The results from this study would suggest that expression of high p53 levels appear to be useful in selecting a group of colorectal cancer patients with a better prognosis. © 1999 Cancer Research Campaign

Keywords: colorectal cancer, p53, immunoassay, luminometric, prognosis, stage III cancer

Full Text

The Full Text of this article is available as a PDF (80.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahnen D. J., Feigl P., Quan G., Fenoglio-Preiser C., Lovato L. C., Bunn P. A., Jr, Stemmerman G., Wells J. D., Macdonald J. S., Meyskens F. L., Jr Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998 Mar 15;58(6):1149–1158. [PubMed] [Google Scholar]
  2. Auvinen A., Isola J., Visakorpi T., Koivula T., Virtanen S., Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer. 1994 Aug;70(2):293–296. doi: 10.1038/bjc.1994.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kressner U., Lindmark G., Gerdin B., Påhlman L., Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 1996 Mar-Apr;16(2):951–957. [PubMed] [Google Scholar]
  4. Nathanson S. D., Linden M. D., Tender P., Zarbo R. J., Jacobsen G., Nelson L. T. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum. 1994 Jun;37(6):527–534. doi: 10.1007/BF02050985. [DOI] [PubMed] [Google Scholar]
  5. Scott N., Sagar P., Stewart J., Blair G. E., Dixon M. F., Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer. 1991 Feb;63(2):317–319. doi: 10.1038/bjc.1991.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  7. Soong R., Grieu F., Robbins P., Dix B., Chen D., Parsons R., House A., Iacopetta B. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res. 1997 Aug;3(8):1405–1411. [PubMed] [Google Scholar]
  8. Starzynska T., Bromley M., Ghosh A., Stern P. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer. 1992 Sep;66(3):558–562. doi: 10.1038/bjc.1992.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Yamaguchi A., Kurosaka Y., Fushida S., Kanno M., Yonemura Y., Miwa K., Miyazaki I. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer. 1992 Dec 15;70(12):2778–2784. doi: 10.1002/1097-0142(19921215)70:12<2778::aid-cncr2820701209>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  10. Yamaguchi A., Nakagawara G., Kurosaka Y., Nishimura G., Yonemura Y., Miyazaki I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer. 1993 Aug;68(2):399–402. doi: 10.1038/bjc.1993.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Zeng Z. S., Sarkis A. S., Zhang Z. F., Klimstra D. S., Charytonowicz E., Guillem J. G., Cordon-Cardo C., Cohen A. M. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994 Oct;12(10):2043–2050. doi: 10.1200/JCO.1994.12.10.2043. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES